UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.289

Sortiert nach

Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)

British journal of cancer, 2013-05, Vol.108 (10), p.1957-1963

2013

Volltextzugriff (PDF)

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma

British journal of cancer, 2009-09, Vol.101 (6), p.967-972

2009

Volltextzugriff (PDF)

Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: An international collaborative meta-analysis

European journal of surgical oncology, 2013-02, Vol.39 (2), p.115-124

2013

Volltextzugriff (PDF)

The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2

Genes & development, 1999-11, Vol.13 (22), p.2928-2933

1999

Volltextzugriff (PDF)

Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase

Science (American Association for the Advancement of Science), 1999-04, Vol.284 (5414), p.657-661

1999

Volltextzugriff (PDF)

A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer

Japanese journal of clinical oncology, 2010-05, Vol.40 (5), p.456-463

2010

Volltextzugriff (PDF)

A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)

Japanese journal of clinical oncology, 2010-01, Vol.40 (1), p.90-93

2010

Volltextzugriff (PDF)

Prognostic factors for stage IVB persistent or recurrent cervical cancer (from the results of the JCOG0505 Trial)

Gynecologic oncology, 2013-07, Vol.130 (1), p.e2-e3

2013

Volltextzugriff (PDF)

Phase III Trial of Upfront Debulking Surgery Versus Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: Japan Clinical Oncology Group Study JCOG0602

Japanese journal of clinical oncology, 2008-01, Vol.38 (1), p.74-77

2008

Volltextzugriff (PDF)

Dynamics of placental ghrelin production and its receptor expression in a Dahl salt-sensitive rat model of intrauterine growth restriction

Placenta (Eastbourne), 2010-05, Vol.31 (5), p.358-364

2010

Volltextzugriff (PDF)

Usefulness of Small Pelvic Field for Stage IB-IIA Uterine Cervical Cancer Patients With Intermediate Recurrent Factors

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S440-S441

2012

Volltextzugriff (PDF)

W167 CHARACTERISTICS OF PREGNANT WOMEN WITH ONE ABNORMAL VALUE ON 75-G ORAL GLUCOSE TOLERANCE TEST

International journal of gynecology and obstetrics, 2012-10, Vol.119 (S3), p.S759-S759

2012

Volltextzugriff (PDF)

Integrated molecular analysis of clear-cell renal cell carcinoma

Nature genetics, 2013-08, Vol.45 (8), p.860

2013

Volltextzugriff (PDF)

Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer

Cytopathology (Oxford), 2015-06, Vol.26 (3), p.157-166

2015

Volltextzugriff (PDF)

The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG)

Japanese journal of clinical oncology, 2011-10, Vol.41 (10), p.1156-1161

2011

Volltextzugriff (PDF)

8042 POSTER Nuclear Y-box Binding Protein-1 Expression, a Predictive Marker of Prognosis, Is Correlated With Activated Signal Transducer and Activator of Transcription-3 Expression and Survival in Cervical Squamous-cell Carcinoma

European journal of cancer (1990), 2011, Vol.47, p.S540-S540

2011

Volltextzugriff (PDF)

Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer

Gynecologic oncology, 2004-05, Vol.93 (2), p.287-291

2004

Volltextzugriff (PDF)

VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases

Genes & development, 2004-12, Vol.18 (24), p.3055-3065

2004

Volltextzugriff (PDF)

Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias

Clinical cancer research, 1998-06, Vol.4 (6), p.1517-1520

1998

Volltextzugriff (PDF)

Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7

The EMBO journal, 2004-05, Vol.23 (10), p.2116-2125

2004

Volltextzugriff (PDF)

UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour

British journal of cancer, 2002-10, Vol.87 (9), p.1006-1012

2002

Volltextzugriff (PDF)

Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients

British journal of cancer, 2002-09, Vol.87 (7), p.796-804

2002

Volltextzugriff (PDF)

Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.5013-5013

2006

Volltextzugriff (PDF)

Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase

Nature cell biology, 2004-12, Vol.6 (12), p.1229-1235

2004

Volltextzugriff (PDF)

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

Cancer, 2000-06, Vol.88 (11), p.2584-2589

2000

Volltextzugriff (PDF)

1 – 25 von 1.289

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(916)
Mit Volltextzugriff
(1.156)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma

Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: An international collaborative meta-analysis

The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2

Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase

A Consensus-based Guideline Defining the Clinical Target Volume for Pelvic Lymph Nodes in External Beam Radiotherapy for Uterine Cervical Cancer

A Phase III Trial of Paclitaxel plus Carboplatin Versus Paclitaxel plus Cisplatin in Stage IVB, Persistent or Recurrent Cervical Cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)

Prognostic factors for stage IVB persistent or recurrent cervical cancer (from the results of the JCOG0505 Trial)

Phase III Trial of Upfront Debulking Surgery Versus Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: Japan Clinical Oncology Group Study JCOG0602

Dynamics of placental ghrelin production and its receptor expression in a Dahl salt-sensitive rat model of intrauterine growth restriction

Usefulness of Small Pelvic Field for Stage IB-IIA Uterine Cervical Cancer Patients With Intermediate Recurrent Factors

W167 CHARACTERISTICS OF PREGNANT WOMEN WITH ONE ABNORMAL VALUE ON 75-G ORAL GLUCOSE TOLERANCE TEST

Integrated molecular analysis of clear-cell renal cell carcinoma

Cytological nuclear atypia classification can predict prognosis in patients with endometrial cancer

The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG)

8042 POSTER Nuclear Y-box Binding Protein-1 Expression, a Predictive Marker of Prognosis, Is Correlated With Activated Signal Transducer and Activator of Transcription-3 Expression and Survival in Cervical Squamous-cell Carcinoma

Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer

VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases

Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias

Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7

UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour

Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients

Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer (JCOG 0102)

Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

Suchergebnisse filtern